A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma.

Ther Clin Risk Manag · 2022 · PMC9275425 · PMID 35837579

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

6 Similarly, the benefit of pembrolizumab plus axitinib and nivolumab plus cabozantinib combinations in the favorable-risk subpopulations of KEYNOTE-426 and CHECKMATE-9ER trials failed to reach significance. 7 , 8 However, in the JAVELIN 101 trial, avelumab plus axitinib showed consistent efficacy in all IMDC risk groups.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.